Compare · MDLN vs QNRX
MDLN vs QNRX
Side-by-side comparison of Medline Inc. (MDLN) and Quoin Pharmaceuticals Ltd. (QNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and QNRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.31B, about 4758.3x QNRX ($9.9M).
- Over the past year, MDLN is down 11.6% and QNRX is down 45.4% - MDLN leads by 33.8 points.
- MDLN has been more active in the news (21 items in the past 4 weeks vs 5 for QNRX).
- MDLN has more recent analyst coverage (25 ratings vs 0 for QNRX).
PerformanceMDLN-11.64%QNRX-64.17%
2025-12-17+0.00%2026-06-09
- Company
- Medline Inc.
- Quoin Pharmaceuticals Ltd.
- Price
- $36.01+6.54%
- $4.81+3.89%
- Market cap
- $47.31B
- $9.9M
- 1M return
- -8.80%
- -23.77%
- 1Y return
- -11.64%
- -45.40%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 21
- 5
- Recent ratings
- 25
- 0
QNRX
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest MDLN
- Principal Accounting Officer Corcoran Jessi L bought $170,750 worth of shares (5,000 units at $34.15) (SEC Form 4)
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
Latest QNRX
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
- SEC Form SCHEDULE 13G filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
- SEC Form 424B3 filed by Quoin Pharmaceuticals Ltd.
- Amendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026